Compare SCSC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCSC | GLUE |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1997 | 2021 |
| Metric | SCSC | GLUE |
|---|---|---|
| Price | $60.36 | $10.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $64.50 | $26.88 |
| AVG Volume (30 Days) | 199.8K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.33 | N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $3,846,260,000.00 | $123,672,000.00 |
| Revenue This Year | $10.38 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | ★ $16.46 | $72.42 |
| Revenue Growth | 7.79 | ★ 63.54 |
| 52 Week Low | $33.76 | $9.68 |
| 52 Week High | $66.78 | $25.77 |
| Indicator | SCSC | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 43.02 |
| Support Level | $58.49 | $9.69 |
| Resistance Level | $63.10 | $12.26 |
| Average True Range (ATR) | 1.74 | 0.59 |
| MACD | -0.17 | 0.25 |
| Stochastic Oscillator | 43.66 | 49.03 |
ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).